SEARCH

SEARCH BY CITATION

References

  • 1
    Noris M, Brioschi S, Caprioli J et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 15421547.
  • 2
    Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100: 1296612971.
  • 3
    Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 20172025.
  • 4
    Neumann HP, Salzmann M, Bohnert-Iwan B et al. Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. J Med Genet 2003; 40: 676681.
  • 5
    Pirson Y, Lefebvre C, Arnout C, Van Ypersele de Strihou C. Hemolytic uremic syndrome in three adult siblings: A familial study and evolution. Clin Nephrol 1987; 28: 250255.
  • 6
    Goodship TH, Liszewski MK, Kemp EJ, Richards A, Atkinson JP. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol Med 2004; 10: 226231.
  • 7
    Nilsson SC, Karpman D, Vaziri-Sani F et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007; 44: 18351844.
  • 8
    Richards A, Kathryn Liszewski M, Kavanagh D et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007; 44: 111122.
  • 9
    Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 12671279.
  • 10
    Fremeaux-Bacchi V, Kemp EJ, Goodship JA et al. The development of atypical HUS is influenced by susceptibility factors in factor H and membrane cofactor protein-evidence from two independent cohorts. J Med Genet 2005; 42: 852856.
  • 11
    Dragon-Durey MA, Fremeaux-Bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 2005; 27: 359374.
  • 12
    Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 10351050.
  • 13
    Ichida S, Yuzawa Y, Okada H, Yoshioka K, Matsuo S. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994; 46: 8996.
  • 14
    Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41: 471419.
  • 15
    Barone GW, Gurley BJ, Abul-Ezz SR, Gokden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42: 202206.
  • 16
    Saikali JA, Truong LD, Suki WN. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3: 229230.
  • 17
    Florman S, Benchimol C, Lieberman K, Burrows L, Bromberg JS. Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen. Pediatr Transplant 2002; 6: 352325.
  • 18
    Lagaaij EL, Cramer-Knijnenburg GF, Van Kemenade FJ, Van Es LA, Bruijn JA, Van Krieken JH. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001; 357: 3337.
  • 19
    Van Poelgeest EP, Baelde HJ, Lagaaij EL et al. Endothelial cell chimerism occurs more often and earlier in female than in male recipients of kidney transplants. Kidney Int 2005; 68: 847853.